Top Page
Defence Therapeutics
(DTC)
Defence Therapeutics (DTC) vs. iShares MSCI Canada ETF (EWC)
Defence Therapeutics Business Overview & Revenue Model
Defence Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -53.16K | -72.34K | -90.92K | -13.82K | 0.00 | 0.00 |
| EBITDA | -3.25M | -3.13M | -12.68M | -6.48M | 0.00 | 0.00 |
| Net Income | -3.62M | -3.52M | -13.19M | -6.76M | -7.34M | -2.86M |
Balance Sheet | ||||||
| Total Assets | 2.77M | 1.65M | 477.75K | 3.53M | 719.67K | 5.61M |
| Cash, Cash Equivalents and Short-Term Investments | 2.32M | 1.23M | 56.55K | 2.79M | 506.70K | 5.45M |
| Total Debt | 2.97M | 1.50M | 1.75M | 1.75M | 0.00 | 0.00 |
| Total Liabilities | 4.18M | 2.91M | 4.06M | 1.97M | 1.11M | 122.26K |
| Stockholders Equity | -1.41M | -1.26M | -3.58M | 1.57M | -387.56K | 5.49M |
Cash Flow | ||||||
| Free Cash Flow | -3.41M | -3.40M | -4.49M | -7.72M | -6.04M | -2.29M |
| Operating Cash Flow | -4.21M | -3.40M | -4.29M | -7.66M | -6.04M | -2.29M |
| Investing Cash Flow | -17.52K | 3.60K | -203.24K | -65.80K | 0.00 | 0.00 |
| Financing Cash Flow | 6.41M | 4.57M | 1.76M | 10.01M | 1.10M | 5.88M |
Defence Therapeutics Technical Analysis
Defence Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | C$183.31M | -29.02 | -66.34% | ― | ― | 59.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | C$32.66M | -14.87 | -8.01% | ― | -26.81% | -161.24% | |
45 Neutral | C$39.40M | -10.17 | ― | ― | ― | 72.92% | |
43 Neutral | $106.70M | -3.53 | -745.66% | ― | ― | ― | |
42 Neutral | C$45.35M | -11.21 | ― | ― | -41.70% | -35.42% |
Defence Therapeutics Corporate Events
Defence Therapeutics announced the successful approval of all matters at its annual general meeting, including the election of directors and the appointment of auditors. The company has granted 800,000 stock options and amended the terms of 967,000 common share purchase warrants, extending their expiry date and adjusting the exercise price. Additionally, Defence has engaged i2i Marketing Group for a two-month online marketing campaign to enhance its market presence.
Defence Therapeutics has announced the formation of its inaugural Scientific Advisory Board (SAB) to guide the advancement of its Accum-enhanced Antibody Drug Conjugate (ADC) programs. The SAB, comprising experts in antibody-based therapeutics and biotechnology, will provide strategic guidance as the company progresses its Accum-enabled ADC programs from preclinical development towards clinical applications. This move is expected to strengthen Defence’s scientific foundation and support its long-term development strategy, potentially enhancing its position in the biotechnology industry.
Defence Therapeutics has announced the conversion of its 8% convertible debentures into 2,607,600 common shares, valued at a total of $1,594,080, upon reaching maturity. This strategic financial move reflects the company’s ongoing efforts to bolster its capital structure, potentially enhancing its market position and operational capabilities in the biotechnology sector.
Defence Therapeutics announced a significant advancement in cancer treatment by enhancing the potency and reducing the toxicity of ADCs through its Accum® technology. Following successful engagements at major industry conferences, the company is set to supply its platform to ADC companies facing challenges with dosing and toxicity, aiming to transform ADC cancer therapies and establish itself as a leader in ADC drug delivery.
Defence Therapeutics announced a successful presentation at the World ADC Conference in San Diego, showcasing new data on its Accum® platform. The presentation highlighted how Accum® enhances intracellular delivery and payload release, boosting the potency and therapeutic index of ADCs. Following the positive response, Defence plans to expand its evaluation of Accum® across various commercial and clinical-stage ADCs, aiming to validate its potential as a universal enhancer for targeted cancer therapies. The company is engaging with industry partners to accelerate these evaluations, which could significantly impact the development of more effective cancer treatments.
Defence Therapeutics has announced promising preclinical results for its Accum®-Kadcyla, a novel version of the ADC Kadcyla®, showing a 20-fold increase in anti-tumor efficacy in HER2-positive breast cancer models compared to Kadcyla® alone. This advancement could potentially shift current ADC therapies from second-line to first-line treatments, offering significant benefits to patients by reducing toxicity and side effects. Following these results, Defence plans to expand its program to additional tumor models and engage with potential pharmaceutical partners.
Defence Therapeutics announced it will present new scientific data on its Accum® technology at the World ADC Conference in San Diego. The Accum® platform improves the intracellular delivery and endosomal escape of therapeutic payloads, addressing limitations of current ADCs and enabling higher potency with reduced off-target toxicity. This advancement could significantly enhance the therapeutic index of ADCs, positioning Defence Therapeutics as a leader in next-generation targeted therapies.
Defence Therapeutics announced its participation in the CPHI Worldwide 2025, a major pharmaceutical trade fair in Frankfurt, Germany. The event presents an opportunity for Defence to engage with potential partners and the global pharma community, explore the latest trends in pharmaceutical manufacturing, and strengthen its international collaborations. The company is also hosting a networking event to foster relationships and explore partnership opportunities, which could enhance its industry positioning and stakeholder engagement.